164 related articles for article (PubMed ID: 1719081)
41. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
[TBL] [Abstract][Full Text] [Related]
42. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
Andersson AC; Holst PJ
J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
[TBL] [Abstract][Full Text] [Related]
43. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.
Allen TM; Jing P; Calore B; Horton H; O'Connor DH; Hanke T; Piekarczyk M; Ruddersdorf R; Mothé BR; Emerson C; Wilson N; Lifson JD; Belyakov IM; Berzofsky JA; Wang C; Allison DB; Montefiori DC; Desrosiers RC; Wolinsky S; Kunstman KJ; Altman JD; Sette A; McMichael AJ; Watkins DI
J Virol; 2002 Oct; 76(20):10507-11. PubMed ID: 12239328
[TBL] [Abstract][Full Text] [Related]
44. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.
Vargas-Inchaustegui DA; Xiao P; Demberg T; Pal R; Robert-Guroff M
Immunology; 2015 Jun; 145(2):288-99. PubMed ID: 25626488
[TBL] [Abstract][Full Text] [Related]
46. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
Meyer D; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
[TBL] [Abstract][Full Text] [Related]
47. Generation of diversity in the hierarchy of T-cell epitope responses following different routes of immunization with simian immunodeficiency virus protein.
Brookes R; Bergmeier LA; Mitchell E; Walker J; Tao L; Klavinskis L; Meyers NJ; Layton G; Adams SE; Lehner T
AIDS; 1995 Sep; 9(9):1017-24. PubMed ID: 8527073
[TBL] [Abstract][Full Text] [Related]
48. Identification of multiple simian immunodeficiency virus (SIV)-specific CTL epitopes in sooty mangabeys with natural and experimentally acquired SIV infection.
Kaur A; Yang J; Hempel D; Gritz L; Mazzara GP; McClure H; Johnson RP
J Immunol; 2000 Jan; 164(2):934-43. PubMed ID: 10623842
[TBL] [Abstract][Full Text] [Related]
49. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.
Gauduin MC; Glickman RL; Ahmad S; Yilma T; Johnson RP
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14031-6. PubMed ID: 10570193
[TBL] [Abstract][Full Text] [Related]
50. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route.
Lehner T; Brookes R; Panagiotidi C; Tao L; Klavinskis LS; Walker J; Walker P; Ward R; Hussain L; Gearing JH
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8638-42. PubMed ID: 7690967
[TBL] [Abstract][Full Text] [Related]
51. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
[TBL] [Abstract][Full Text] [Related]
52. T cell responses in macaques after vaginal immunization with particulate SIV p27 antigen.
Panagiotidi C; Bergmeier LA; Gearing AJ; Adams SE; Lehner T
Adv Exp Med Biol; 1995; 371B():1575-80. PubMed ID: 7502859
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins.
Anderson MJ; Porter DC; Moldoveanu Z; Fletcher TM; McPherson S; Morrow CD
AIDS Res Hum Retroviruses; 1997 Jan; 13(1):53-62. PubMed ID: 8989427
[TBL] [Abstract][Full Text] [Related]
54. Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.
Li H; Hai Y; Lim SY; Toledo N; Crecente-Campo J; Schalk D; Li L; Omange RW; Dacoba TG; Liu LR; Kashem MA; Wan Y; Liang B; Li Q; Rakasz E; Schultz-Darken N; Alonso MJ; Plummer FA; Whitney JB; Luo M
PLoS One; 2018; 13(8):e0202997. PubMed ID: 30153293
[TBL] [Abstract][Full Text] [Related]
55. Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.
Venturini S; Mosier DE; Burton DR; Poignard P
J Virol; 2002 Jul; 76(14):6987-99. PubMed ID: 12072499
[TBL] [Abstract][Full Text] [Related]
56. Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.
Korioth-Schmitz B; Perley CC; Sixsmith JD; Click EM; Lee S; Letvin NL; Frothingham R
Vaccine; 2015 Oct; 33(42):5715-5722. PubMed ID: 26192357
[TBL] [Abstract][Full Text] [Related]
57. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants.
Zhao J; Lou Y; Pinczewski J; Malkevitch N; Aldrich K; Kalyanaraman VS; Venzon D; Peng B; Patterson LJ; Edghill-Smith Y; Woodward R; Pavlakis GN; Robert-Guroff M
Vaccine; 2003 Sep; 21(25-26):4022-35. PubMed ID: 12922139
[TBL] [Abstract][Full Text] [Related]
58. Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus.
Gotch FM; Hovell R; Delchambre M; Silvera P; McMichael AJ
AIDS; 1991 Mar; 5(3):317-20. PubMed ID: 2059372
[TBL] [Abstract][Full Text] [Related]
59. RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.
Chang WLW; Deere JD; Kieu HT; Castillo LD; Machmach K; Shen X; Tomaras GD; Shacklett BL; Barry PA; Hartigan-O'Connor DJ; Sparger EE
Sci Rep; 2020 Aug; 10(1):14056. PubMed ID: 32820216
[TBL] [Abstract][Full Text] [Related]
60. Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid.
Giraldo-Vela JP; Bean AT; Rudersdorf R; Wallace LT; Loffredo JT; Erickson P; Wilson NA; Watkins DI
Immunogenetics; 2010 Oct; 62(10):701-7. PubMed ID: 20812010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
